Pfizer and BioNTech file Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine with FDA

22 August 2022
biontech-large-1

Following in the steps of US mRNA biotech Moderna (Nasdaq: MRNA), which last week gained a first regulator approval for its bivalent vaccine, now BioNTech (Nasdaq: BNTX) and Pfizer (NYSE: PFE) say they have completed their submission to the US Food and Drug Administration (FDA) today requesting an Emergency Use Authorization of a 30µg booster dose of an Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine for individuals 12 years and older.

The application is based on guidance from the FDA to include both clinical data from the companies’ bivalent Omicron BA.1-adapted vaccine and pre-clinical and manufacturing data from the bivalent Omicron BA.4/BA.5-adapted vaccine. This is aiming to address the continued evolution of SARS-CoV-2.

The companies have already generated mega-billion dollars-worth of sales with their COVID-19 vaccine Comirnaty.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology